Aims Some recent studies have reported superior outcomes for diabetic patients following coronary bypass surgery compared with coronary angioplasty. However, the available data are conflicting, are based on relatively small numbers of diabetic patients, and have limited duration of follow-up. The aims of this study were to compare risk adjusted long-term survival in diabetic patients following first-time revascularization via either coronary bypass surgery or coronary angioplasty; and, to identify variables independently associated with mortality.
Introduction
Diabetes is becoming increasingly prevalent as the American population grows older, more obese, and more sedentary [1] . Cardiovascular disease accounts for 80% of all deaths among diabetics [2] . Diabetics have a worse long-term outcome after either percutaneous transluminal coronary angioplasty [3] [4] [5] or coronary artery bypass graft surgery [6] compared with nondiabetics. Recently, the Bypass Angioplasty Revascularization Investigation, a randomized clinical trial, showed increased 5-year mortality among diabetics after angioplasty compared with bypass surgery [7] . On the other hand, another randomized study, the Emory Angioplasty vs Surgery Trial (EAST) showed no difference in survival for diabetics following angioplasty or bypass surgery [8] . However, neither of these studies included comparative outcomes after revascularization in diabetics as a pre-specified end-point, and both studies involved a relatively small number of diabetic patients.
We have sought to elucidate this controversy by studying two large single-institution experiences, one for angioplasty and the other for bypass surgery using a multi-variable risk-adjusted time-related methodology. Additionally, because it seems unlikely that every diabetic patient who undergoes revascularization should need bypass surgery, we tried to identify characteristics of diabetic patients whose outcomes after angioplasty were as good, or better, than after bypass surgery.
Methods
This was a two-centre database study involving consecutive bypass surgery patients from the Gasthuisberg University Hospital, Leuven, Belgium and angioplasty patients from the Mid America Heart Institute at St. Luke's Hospital in Kansas City, Missouri. The two databases were prospectively collected in an ongoing fashion. In 1993 and 1994, the data were sent to the University of Alabama at Birmingham where data collection, statistical analysis and modelling were performed.
At Gasthuisberg University Hospital, Katholieke Universiteit, Leuven, Belgium, 9600 consecutive patients underwent first time isolated bypass surgery between 1971 and 1992. The angioplasty group was comprised of 6209 consecutive patients who underwent first time coronary angioplasty between June 1980 and December 1991 in the Mid America Heart Institute in Kansas City, Missouri. Multivariable time-related analyses in the hazard function domain of risk factors for death have been reported for both the bypass surgery and angioplasty groups [9] [10] [11] . Of the total of 15 809 patients, 1938 (12%) were known to be diabetic at baseline. This included 882 of the angioplasty patients (14%) and 1056 (11%) of the bypass surgery patients. The percentage of patients in both the angioplasty and bypass surgery groups who were treated with diet alone, oral agents, or insulin are outlined in Table 1 . Of the angioplasty diabetics receiving oral diabetic treatment, all received sulfonylurea agents. Of the Leuven bypass surgery patients receiving oral treatment, 248 received sulfonylurea agents, 35 Metformin, and 11 both.
Follow-up
The patients undergoing bypass surgery were followed cross-sectionally between January 1993 and July 1994, with a common closing date of 1 January 1993. Follow-up was 99·9% complete. Mean follow-up was 7·1 4·3 (SD) years (6·6 4·3 among diabetics). The patients undergoing angioplasty were followed crosssectionally between October 1991 and February 1992. Follow-up was 98·3% complete. Mean follow-up was 5·0 2·8 (SD) years (4·6 2·7 among diabetics).
Direct comparisons
Unadjusted comparison was performed using KaplanMeier non-parametric life table methodology [12] Comprehensive risk-adjusted comparisons were performed to address the possibility that baseline differences and selection biases accounted for the differences in mortality in patients undergoing either bypass surgery at Leuven or angioplasty at the Mid America Heart Institute by use of multivariable time-related analysis [13, 14] The analysis was performed with all 15 809 patients from the two databases, using only variables common to both.
Identifying when angioplasty is equivalent to or better than bypass surgery
Predicted 5-year survival for each diabetic angioplasty patient undergoing angioplasty was calculated using the interaction equation for the combined data set and each patient's individual characteristics. The equation was solved twice: once for angioplasty as it was actually performed for that patient and again as if each patient had received a bypass surgery operation on the same date using one arterial graft, and receiving complete revascularization. The survival estimates were compared and patients whose estimated survival was a good or better with angioplasty as with surgery were identified. Having identified such patients, a multivariable logistic regression analysis was performed to identify factors associated with a good outcome following angioplasty among diabetics.
Results

Risk-unadjusted survival comparisons
The baseline characteristics of the 1938 diabetic patients undergoing angioplasty and bypass surgery are compared in Table 2 . Complete revascularization was achieved in 51% of angioplasty patients and 82% of bypass surgery patients (P<0·0001). Long-term riskunadjusted survival among diabetics with coronary artery disease was worse than for non-diabetics with coronary artery disease whether treated by angioplasty or bypass surgery ( Fig. 1 ).
In general, risk-unadjusted long-term survival of diabetic patients was worse after angioplasty than after 
Risk-adjusted survival comparisons
By multivariable analysis, using interaction terms (see Methods), diabetic patients treated with oral agents were at lower risk for death after bypass surgery than after angioplasty. The risk-adjusted ten-year survival for subgroups treated with oral agents were 75% and 62% in bypass surgery and angioplasty groups, respectively. In contrast, the risk-adjusted 10-year survival for diettreated (84% vs 81%) and insulin-treated diabetics (63% vs 64%) were similar for both the angioplasty and bypass surgery groups. The superiority of bypass surgery observed by risk-unadjusted comparison in diet-treated and insulin-treated diabetics is largely explained by the higher prevalence of compete revascularization achieved by surgery. Additionally, the use of the internal mammary artery for grafting the left anterior descending artery confirmed a significant survival benefit over patients receiving vein grafts only or angioplasty (Fig. 2) .
Angioplasty equivalent to or better than bypass surgery
Of the 882 diabetic angioplasty patients, 98 (11%) were predicted by the statistical analysis to have an equivalent or better 5-year survival after angioplasty compared to bypass surgery. The model predicted that the diabetic patients who will survive as well or longer following angioplasty (compared with bypass surgery) are those at the extremes of age (i.e. very young or very old), with complete revascularization with angioplasty, normal renal function, very poor left ventricular function, nonsmoking status and therapy that did not include sulfonylureas. The formula in the Appendix can be used to compute the probability of survival following angioplasty or bypass surgery in specific patients. Figure 3 compares predicted survival after angioplasty or bypass surgery for otherwise identical sulfonylurea-treated diabetic patients. In this subset, angioplasty results in higher risk of death during follow-up. In contrast, Fig. 4 illustrates otherwise identical young, diet-treated, nonsmoking diabetic patients, completely revascularized, who have equivalent long-term survival whether managed by angioplasty or bypass surgery.
Discussion
In this large retrospective clinical study, diabetic patients who underwent initial angioplasty rather than bypass surgery were, as a group, at higher risk of death during ten-year follow-up. The risk-unadjusted 5-year survival curves for the pharmacologically treated diabetic patients in this group who underwent revascularization with either bypass surgery or angioplasty (83% vs 74%, respectively, Fig. 5 ) were similar to the 5-year survival rates in the Bypass Angioplasty Revascularization. Investigation study [7] (80% vs 65%). Although the differences in both studies were statistically significant, our study involved approximately five times as many diabetic patients.
Significant heterogenicity was present in longterm survival after revascularization of diabetics patients. The ten-year survival advantage for bypass surgery over angioplasty was magnified for diabetics treated with oral agents compared with those diabetic patients treated with diet alone or with insulin therapy. This suggests that oral sulfonylurea therapy was associated with a worse outcome after angioplasty compared with bypass surgery. Although potential explanations for this finding are speculative, sulfonylurea agents (the only available oral therapy for diabetics in the United States during the time course of this study) have, for 
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over 20 years, been suspected of increasing cardiovascular mortality. During the 1970s, the University Group Diabetes Program concluded that tolbutamide increased death from cardiovascular disease in a prospective study [16] . A recent study showed a similar trend for increased cardiovascular events in Type 2 diabetic patients randomized to intensive glycaemic control using sulfonylurea therapy and insulin compared with controls [17] . Experimental data have also renewed concerns about the cardiovascular safety of sulfonylurea therapy for Type 2 diabetes. Sulfonylureas lower glucose levels by closing the adenosine triphosphate sensitive potassium channels which enhances insulin secretion from the beta cells of the pancreas [18] . The closing of these potassium ion channels prolongs myocardial refractoriness, possibly predisposing to arrhythmias, and also exacerbates the consequences of myocardial ischaemia and infarction by mitigating ischaemic preconditioning [18] [19] [20] [21] . Additionally, by increasing insulin levels, sulfonylureas may increase atherogenesis and its complications.
In the current study, long-term survival was considerably better in the bypass surgery strategy than among diabetics who underwent angioplasty. However, 11% of diabetics were predicted to have equivalent or better survival after angioplasty than by pass surgery. Younger, non-smoking, diabetic patients with more complete revascularization and normal renal function had long-term outcomes after angioplasty that were equivalent or better than bypass surgery. Other factors that favoured a good outcome with angioplasty included diabetic therapy that did not include a sulfonylurea and very poor left ventricular function.
Some diabetics who are in need of coronary revascularization may not be a technical candidate for bypass surgery and/or may be well suited for angioplasty. The current study suggests that diabetic patients with discrete disease that can be completely revascularized with angioplasty can be candidates for angioplasty if other clinical factors are favourable. In other studies including diabetic and non-diabetic patients, the ability to achieve complete revascularization with angioplasty [22, 23] has been associated with long-term outcomes as good or better after angioplasty compared with bypass surgery. Current cigarette smokers [24] females [3] and patients with impaired renal function [25] are subgroups that have all been shown previously to have suboptimal outcomes after elective angioplasty in general populations. In a diabetic patient, these factors should all be considered as variables favouring bypass surgery over angioplasty. The very young, who are likely to have discrete disease, and the very old, who are at increased risk for peri-operative morbidity and mortality with bypass surgery, are subgroups of diabetics that may do as well with angioplasty as with bypass surgery.
Somewhat surprisingly, the presence of severe left ventricular dysfunction was a factor favouring angioplasty over bypass surgery in this study of diabetic patients. Studies comparing bypass surgery and medical therapy consistently found that left ventricular dysfunction was one of the strongest indicators for improved survival after bypass surgery compared with conservative medical treatment [26] [27] [28] . However, more recent randomized trials showed no difference in survival in patients with left ventricular dysfunction randomized to angioplasty or bypass surgery [29] Left ventricular dysfunction does increase peri-operative risks for bypass surgery; a risk that is magnified in the diabetic patient.
The risk of restenosis after angioplasty is higher in diabetics than non-diabetics [30, 31] possibly related to exaggerated intimal hyperplasia after vessel injury. A recent study showed lower restenosis rates in diabetics after stenting than angioplasty [32] . No patient in the angioplasty group received stents in the current study. 
Limitations
These results must be considered hypothesis-generating rather than definitive. A randomized trial (The BARI-II) comparing angioplasty and bypass surgery in diabetic patients is currently in progress and should help to clarify these issues. In risk adjustment, we have assumed that the bypass surgery operation would be done using widely accepted modern standards in every patient (attempted complete revascularization and an internal mammary artery graft for the left anterior descending). However, in individual patients, the ideal operation may not always be possible and thus our estimates of surgical survival for patients treated with angioplasty may be biased toward a more favourable surgical result. The bypass surgery was performed in Leuven, Belgium, whereas the angioplasty was performed in Kansas City, Missouri, in the United States. This difference may have influenced long-term outcomes independent of the revascularization procedures. However, comprehensive patient-by-patient risk adjustment should account for most of the important differences in the patient groups.
One important differences between the two groups was the therapy available for treating Type 2 diabetes mellitus. In the United States, during the time frame during which these patients underwent angioplasty, sulfonylurea therapy was the only oral medication available for treating diabetes. On the other hand, metformin was available in Belgium, though used in only a small fraction of the orally-treated diabetics. It is possible that the difference between bypass surgery and angioplasty for patients treated with oral agents was in part, a function of the type of oral therapy utilized, and not just the type of revascularization chosen; however, this was not identified as such in the multivariable analyses.
